BrainsWay Ltd. is a global medical technology company focused on the development and commercialization of non-invasive neurostimulation devices for the treatment of psychiatric, neurological, and addiction disorders. The company's core product is based on its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which utilizes a patented H-coil technology to deliver magnetic pulses deeper and broader into the brain compared to traditional TMS systems. BrainsWay generates revenue primarily through the sale and leasing of its Deep TMS systems, as well as through the sale of add-on treatment helmets (coils) and usage-based fees. The company's systems have received FDA clearance for multiple indications, including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction, and are utilized in clinics and hospitals globally. Geographically, the United States represents the company's largest and most significant market, though it maintains a growing installed base internationally. BrainsWay's competitive position is driven by its extensive clinical evidence, exclusive licensing of the H-coil technology originally patented by the U.S. National Institutes of Health (NIH), and its expanding pipeline of clinical trials targeting additional indications such as PTSD and Alzheimer's disease.
